Core binding factor acute myeloid leukaemia and c-KIT mutations

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Core binding factor acute myeloid leukaemia (CBF AML) is a subtype with a generally good prognosis.
• Activating c-KIT mutations are implicated in increased relapse risk and reduced survival in some AML subtypes.
• The prognostic significance of c-KIT mutations in CBF AML requires further investigation.

Purpose of the Study:

• To determine the incidence of c-KIT mutations in de novo CBF AML.
• To evaluate the prognostic value of c-KIT mutations on overall survival (OS) and disease-free survival (DFS) in CBF AML.
• To explore associations between c-KIT mutations and clinical parameters.

Main Methods:

• Retrospective analysis of 23 adult de novo CBF AML patients (14 inv(16), 9 t(8;21)).
• Analysis of c-KIT mutations in specific exons (8, 9, 10, 11, 13, 14, 17) using PCR and direct sequencing.
• Correlation of mutation status with clinical data, including cytogenetics, remission, WT1 levels, LDH, OS, and DFS.

Main Results:

• c-KIT mutations were detected in 7/23 (30.4%) patients (4 with inv(16), 3 with t(8;21)).
• No significant difference in c-KIT mutation status was found based on specific CBF AML subtypes or additional cytogenetic abnormalities.
• Higher lactate dehydrogenase (LDH) levels were observed in c-KIT mutated patients (p=0.01), but OS and DFS were similar between mutated and non-mutated groups.

Conclusions:

• CBF AML maintains a better prognosis than other AML types, and inv(16) AML shows better DFS than t(8;21) AML.
• c-KIT mutational status did not demonstrate prognostic value for OS or DFS in this cohort of CBF AML patients.
• Elevated LDH in mutated CBF AML suggests potentially more active cellular proliferation.